Current status and advances of immunotherapy in nasopharyngeal carcinoma.

Ther Adv Med Oncol · 2022 · PMC9083041 · PMID 35547095

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

108 Although the plasma EBV DNA clearance and the increasing or decreasing trend of EBV DNA during the first month with nivolumab monotherapy did not differ significantly in terms of efficacy, more responders showed a decreasing trend of plasma EBV DNA.

also in 47,180 other papers

showed a trendno p-value reported

Although the study did not meet the primary endpoint, pembrolizumab showed a trend of better OS and a lower incidence of treatment-related adverse events.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.